Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Casticin inhibits the activity of transcription factor Sp1 and the methylation of RECK in MGC803 gastric cancer cells.

Yang F, He K, Huang L, Zhang L, Liu A, Zhang J.

Exp Ther Med. 2017 Feb;13(2):745-750. doi: 10.3892/etm.2016.4003. Epub 2016 Dec 27.

2.

Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.

Momparler RL, Côté S, Momparler LF, Idaghdour Y.

Front Oncol. 2017 Feb 15;7:19. doi: 10.3389/fonc.2017.00019. eCollection 2017.

3.

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ.

Mol Cancer Ther. 2017 Feb;16(2):397-407. doi: 10.1158/1535-7163.MCT-16-0588. Epub 2016 Dec 15.

PMID:
27980103
4.

Transcriptional Selectivity of Epigenetic Therapy in Cancer.

Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ.

Cancer Res. 2017 Jan 15;77(2):470-481. doi: 10.1158/0008-5472.CAN-16-0834. Epub 2016 Nov 22.

PMID:
27879268
5.

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP.

Cancer Res. 2016 Mar 15;76(6):1494-505. doi: 10.1158/0008-5472.CAN-14-2391. Epub 2015 Dec 30.

6.

Epigenetic synergy between decitabine and platinum derivatives.

Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JP.

Clin Epigenetics. 2015 Sep 11;7:97. doi: 10.1186/s13148-015-0131-z. eCollection 2015.

7.

Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.

Jones TI, King OD, Himeda CL, Homma S, Chen JC, Beermann ML, Yan C, Emerson CP Jr, Miller JB, Wagner KR, Jones PL.

Clin Epigenetics. 2015 Mar 29;7:37. doi: 10.1186/s13148-015-0072-6. eCollection 2015.

8.

Persistence of furan-induced epigenetic aberrations in the livers of F344 rats.

de Conti A, Kobets T, Tryndyak V, Burnett SD, Han T, Fuscoe JC, Beland FA, Doerge DR, Pogribny IP.

Toxicol Sci. 2015 Apr;144(2):217-26. doi: 10.1093/toxsci/kfu313. Epub 2014 Dec 23.

9.

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.

Momparler RL, Côté S, Momparler LF, Idaghdour Y.

Clin Epigenetics. 2014 Oct 1;6(1):19. doi: 10.1186/1868-7083-6-19. eCollection 2014.

10.

Human factors and pathways essential for mediating epigenetic gene silencing.

Poleshko A, Kossenkov AV, Shalginskikh N, Pecherskaya A, Einarson MB, Marie Skalka A, Katz RA.

Epigenetics. 2014 Sep;9(9):1280-9. doi: 10.4161/epi.32088. Epub 2014 Aug 4.

11.

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples.

Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II.

Clin Epigenetics. 2014 Jul 3;6(1):13. doi: 10.1186/1868-7083-6-13. eCollection 2014.

12.

A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene.

Cui Y, Hausheer F, Beaty R, Zahnow C, Issa JP, Bunz F, Baylin SB.

Cancer Res. 2014 Jul 15;74(14):3834-43. doi: 10.1158/0008-5472.CAN-13-2287. Epub 2014 May 29.

13.

Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies.

Wong YF, Jakt LM, Nishikawa S.

PLoS One. 2013 Aug 6;8(8):e71099. doi: 10.1371/journal.pone.0071099. Print 2013.

14.

Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure.

Hesson LB, Patil V, Sloane MA, Nunez AC, Liu J, Pimanda JE, Ward RL.

PLoS Genet. 2013;9(7):e1003636. doi: 10.1371/journal.pgen.1003636. Epub 2013 Jul 25.

15.

Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Lim SP, Kumar R, Akkamsetty Y, Wang W, Ho K, Neilsen PM, Walther DJ, Suetani RJ, Prestidge C, Callen DF.

BMC Cancer. 2013 Mar 13;13:113. doi: 10.1186/1471-2407-13-113.

16.

3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models.

Gertych A, Oh JH, Wawrowsky KA, Weisenberger DJ, Tajbakhsh J.

BMC Pharmacol Toxicol. 2013 Feb 11;14:11. doi: 10.1186/2050-6511-14-11.

17.

Genomic impact of transient low-dose decitabine treatment on primary AML cells.

Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, Lichti CF, Meyer MR, Townsend RR, Wilson RK, Mardis ER, Ley TJ.

Blood. 2013 Feb 28;121(9):1633-43. doi: 10.1182/blood-2012-09-459313. Epub 2013 Jan 7.

18.

Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax.

Bracht JR, Perlman DH, Landweber LF.

Genome Biol. 2012 Oct 17;13(10):R99. doi: 10.1186/gb-2012-13-10-r99.

19.

Epigenetics of colorectal cancer.

Goel A, Boland CR.

Gastroenterology. 2012 Dec;143(6):1442-1460.e1. doi: 10.1053/j.gastro.2012.09.032. Epub 2012 Sep 20. Review.

20.

Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions.

Yang X, Noushmehr H, Han H, Andreu-Vieyra C, Liang G, Jones PA.

PLoS Genet. 2012;8(3):e1002604. doi: 10.1371/journal.pgen.1002604. Epub 2012 Mar 29.

Supplemental Content

Support Center